| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 15% | +37% | $11,393,153 | +$3,625,000 | 7,857,347 | +47% | Lynx1 Capital Management LP | 30 Jun 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 10% | $8,421,666 | 5,263,541 | BVF PARTNERS L P/IL | 31 Mar 2025 | |||
| K2 HealthVentures Equity Trust LLC | 6.9% | $5,764,320 | 3,602,700 | K2 HealthVentures Equity Trust LLC | 31 Dec 2024 | |||
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.1% | $5,600,000 | 3,500,000 | Adage Capital Management, L.P. | 31 Dec 2024 | |||
| Adage Capital Management, L.P. | 2.5% | $1,957,500 | 1,350,000 | Adage Capital Management, L.P. | 30 Jun 2025 | |||
| BlackRock, Inc. | 1.8% | -72% | $1,475,894 | -$2,875,873 | 958,373 | -66% | BlackRock, Inc. | 30 Jun 2025 |
| EcoR1 Capital, LLC | 1.3% | $1,060,533 | 662,833 | EcoR1 Capital, LLC | 31 Mar 2025 |
As of 31 Dec 2025, 58 institutional investors reported holding 30,668,719 shares of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX). This represents 59% of the company’s total 52,382,313 outstanding shares.
The largest institutional shareholders of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) together control 57% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 15% | 8,019,148 | +2.1% | 1.6% | $8,019,148 |
| BVF INC/IL | 10% | 5,226,074 | 0% | 0.18% | $5,226,074 |
| BAKER BROS. ADVISORS LP | 5.3% | 2,784,792 | 0% | 0.02% | $2,784,792 |
| VANGUARD GROUP INC | 4.7% | 2,475,733 | +6.8% | 0% | $2,475,733 |
| BlackRock, Inc. | 3.5% | 1,848,695 | -22% | 0% | $1,848,695 |
| Aberdeen Group plc | 3.4% | 1,785,241 | +32% | 0% | $1,785,241 |
| Deer Management Co. LLC | 2.4% | 1,245,504 | 0% | 0.12% | $1,245,504 |
| RENAISSANCE TECHNOLOGIES LLC | 2.2% | 1,141,069 | +37% | 0% | $1,141,069 |
| TWO SIGMA INVESTMENTS, LP | 1.2% | 651,179 | +55% | 0% | $651,179 |
| DC Funds, LP | 1.2% | 630,000 | 0% | 43% | $630,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 562,153 | -0.97% | 0% | $562,360 |
| MILLENNIUM MANAGEMENT LLC | 0.77% | 403,618 | -13% | 0% | $403,618 |
| JANE STREET GROUP, LLC | 0.74% | 388,284 | +378% | 0% | $388,284 |
| TWO SIGMA ADVISERS, LP | 0.68% | 353,900 | +23% | 0% | $353,900 |
| MARSHALL WACE, LLP | 0.65% | 339,240 | +628% | 0% | $339,240 |
| GSA CAPITAL PARTNERS LLP | 0.43% | 226,164 | 0.02% | $226,000 | |
| MORGAN STANLEY | 0.43% | 225,829 | -73% | 0% | $225,829 |
| XTX Topco Ltd | 0.42% | 219,001 | +1142% | 0.01% | $219,001 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.41% | 216,133 | +171% | 0% | $216,133 |
| STATE STREET CORP | 0.4% | 207,313 | +5.1% | 0% | $207,313 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.36% | 188,152 | 0% | $188,152 | |
| CITADEL ADVISORS LLC | 0.31% | 162,877 | -58% | 0% | $162,877 |
| BROWN BROTHERS HARRIMAN & CO | 0.27% | 143,051 | 0% | 0% | $143,051 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.22% | 115,400 | -18% | 0% | $115,400 |
| NORTHERN TRUST CORP | 0.19% | 98,198 | -0.36% | 0% | $98,198 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 30,668,719 | $30,666,797 | -$7,264,797 | $1.00 | 58 |
| 2025 Q3 | 34,601,160 | $62,910,264 | -$1,894,623 | $1.82 | 72 |
| 2025 Q2 | 35,724,879 | $51,820,655 | -$5,881,550 | $1.45 | 79 |
| 2025 Q1 | 40,135,840 | $55,389,702 | -$2,855,488 | $1.38 | 92 |
| 2024 Q4 | 41,522,755 | $126,231,784 | -$5,917,073 | $3.04 | 87 |
| 2024 Q3 | 41,835,445 | $208,343,506 | +$256,552 | $4.98 | 86 |
| 2024 Q2 | 41,438,662 | $242,461,718 | +$40,505,361 | $5.85 | 78 |
| 2024 Q1 | 34,291,369 | $272,339,183 | +$19,079,789 | $7.94 | 65 |
| 2023 Q4 | 31,912,819 | $186,051,742 | +$7,213,515 | $5.83 | 54 |
| 2023 Q3 | 28,588,231 | $73,196,468 | +$2,177,876 | $2.56 | 32 |
| 2023 Q2 | 27,951,619 | $69,879,871 | +$45,817,232 | $2.50 | 28 |
| 2023 Q1 | 9,667,555 | $20,309,551 | +$609,616 | $2.10 | 28 |
| 2022 Q4 | 9,519,305 | $14,788,379 | -$121,391 | $1.55 | 28 |
| 2022 Q3 | 9,508,092 | $29,003,732 | -$530,741 | $3.05 | 24 |
| 2022 Q2 | 9,682,082 | $30,449,817 | +$1,528,632 | $3.14 | 23 |
| 2022 Q1 | 9,407,022 | $26,340,000 | -$1,500,189 | $2.80 | 24 |
| 2021 Q4 | 9,861,945 | $44,380,000 | -$2,457,435 | $4.50 | 28 |
| 2021 Q3 | 9,504,939 | $78,230,000 | +$78,229,998 | $8.34 | 25 |